Medically reviewed by Doru Paul, MD CD20 is a CD marker—a molecule on the cell surface that can be used to identify and type ...

Crypto markets see over $300M in liquidations as investors flee risk ahead of April policy changes and over concerning ...

In the latest move to cement its “immunology powerhouse” status, Sanofi is handing ove | The CD20-directed antibody, dubbed ...

The deal is the latest in a series of Sanofi investments in its immunology portfolio. According to Sanfoi, DR-0201 can ...

Markets have been heavy since Thursday as President Donald Trump warned of deeper tariffs on Canada and the European Union in ...

Sanofi (NASDAQ:SNY) has agreed to acquire an immunology drug from clinical-stage biopharmaceutical company Dren Bio for up to ...

Sanofi is set to acquire DR-0201 from Dren Bio for up to $1.9 billion, aiming to expand its autoimmune disease pipeline with ...

The results of Phase III trials of the CD20-targeted human monoclonal antibody (mAb) ofatumumab in rheumatoid arthritis and non-Hodgkin's lymphoma (NHL) dampen hopes on the potential of the drug ...

The crypto market is extending yesterday's slide as investors anticipate the impact of President Donald Trump’s reciprocal ...

CD20 × CD3 bispecific antibodies bind to both CD20 on malignant B cells and CD3 on T cells, bringing them into close proximity, which triggers T cell-mediated killing of the targeted B cells.

TG Therapeutics, Inc.’s TGTX share price has surged by 10.20%, which has investors questioning if this is right time to sell.

The company said that ZAMTO Cell is designed to target both CD19 and CD20, which could improve treatment efficacy.